GLP-1/GIP/glucagon receptor (triple) drugs for Obesity

5 tracked GLP-1/GIP/glucagon receptor (triple) drugs in the Obesity race. The class explanation lives on the GLP-1/GIP/glucagon receptor (triple) page; the full indication pipeline across every mechanism is on the Obesity page.

2 Phase 32 Phase 21 Phase 1

Head-to-head evidence: Efocipegtrutide vs HM15275 · Efocipegtrutide vs HRS-4729 · Efocipegtrutide vs UBT251 · Efocipegtrutide vs retatrutide · HM15275 vs HRS-4729 · HM15275 vs UBT251

The roster

← all GLP-1/GIP/glucagon receptor (triple) drugs